Is Cybin Inc. (CYBN.NE) a Buy, Sell, or Hold?
NEO : CYBN.NE
Cybin Inc.
$10.1 CAD
-$0.13 (-1.27%)
- Volume
- 5.2K
- Average Volume
- 19.42K
- Market Capitalization
- $244.48M
- P/E Ratio
- -1.74
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $15.27
- Year Low
- $5.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.52
Company Overview
NEO
Eric So
Medical - Pharmaceuticals
Healthcare
CYBN.NE
100
CA
CAD
Liquidity Metrics
0.00
9.52
9.52
8.12
0.00
Sales & Valuation
-$
0.00
1.56
-1.38
-2.51
Profitability
-$4.22
-$146.67M
0.00%
0.00%
-72.37%
-58.36%
P/E Metrics
-1.74
-0.07
-0.07
Analyst Price Target & Rating
2/5
3 Analysts
%
Financial Health Scores
3.79
2/9
$165.26M
$251.34M
$19.39M
-$135.25M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Paul Glavine | Co-Founder, Chief Growth Officer & Director |
| Lori Challenger | Chief Compliance, Ethics & Administrative Officer |
| Gabriel Fahel | Chief Legal Officer & Corporate Secretary |
| George Tziras | Chief Business Officer |
| Greg Cavers | Chief Financial Officer |
| John Kanakis | Co-Founder |
| Alex L. Nivorozhkin | Chief Scientific Officer |
| Aaron Bartlone | Chief Operating Officer |
| Eric So | Co-Founder, Interim Chief Executive Officer, President & Executive Chairman |
| Sara Brittany Somerset | Chief Communications Officers |
Poll Results
No votes yet today — be the first to share your view!
About Cybin Inc. (NEO:CYBN.NE) Stock
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada. ...
Frequently Asked Questions
-
What is the current Cybin Inc. (CYBN.NE) stock price?
-
Cybin Inc.(NEO:CYBN.NE) stock price is $10.1 in the last trading session. During the trading session, CYBN.NE stock reached the peak price of $15.27 while $5.3 was the lowest point it dropped to. The percentage change in CYBN.NE stock occurred in the recent session was --1.27% while the dollar amount for the price change in CYBN.NE stock was -$0.13.
-
CYBN.NE's industry and sector of operation?
-
The NEO listed CYBN.NE is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of CYBN.NE?
-
Paul Glavine | Co-Founder, Chief Growth Officer & Director
Lori Challenger | Chief Compliance, Ethics & Administrative Officer
Gabriel Fahel | Chief Legal Officer & Corporate Secretary
George Tziras | Chief Business Officer
Greg Cavers | Chief Financial Officer -
How many employees does CYBN.NE have?
-
Number of CYBN.NE employees currently stands at 100. CYBN.NE operates from 100 King Street West, Suite 5600, Toronto, ON M5X 1C9, CA.
-
Link for CYBN.NE official website?
-
Official Website of CYBN.NE is: https://www.cybin.com
-
How do I contact CYBN.NE?
-
CYBN.NE could be contacted at phone #908 764 8385 and can also be accessed through its website. CYBN.NE operates from 100 King Street West, Suite 5600, Toronto, ON M5X 1C9, CA.
-
How many shares of CYBN.NE are traded daily?
-
The average number of CYBN.NE shares traded daily for last 3 months was 19.42K.
-
What is the market cap of CYBN.NE currently?
-
The market value of CYBN.NE currently stands at $244.48M with its latest stock price at $10.1